PRMT1 also methylates RIP3 at arginine 486, thereby inhibiting the interaction between RIP3 and RIP1, which suppresses necrosome formation and downstream necroptotic signaling, eventually limiting tumor immune evasion [98]. Here, PRMT1 is linked to neoplasm.